

TAYSHAGTX.COM

3000 Pegasus Park Drive, Suite 1430  
Dallas, Texas 75247 USA



October 26, 2022

Dear Rett Community,

We are pleased to share that Taysha announced a strategic investment by Astellas Pharma to support the advancement of Taysha’s investigational gene therapy program for Rett syndrome. Under the terms of the deal, Astellas will invest a total of \$50 million and will receive an exclusive option to license Taysha’s program for Rett syndrome.

“We are excited to enter this strategic investment with Astellas, a premier biopharmaceutical company with global research & development, manufacturing, and commercial capabilities, including gene therapy experience. This investment strengthens our commitment to the Rett community.”

- RA Session II, Founder, President, and CEO, Taysha Gene Therapies

Taysha’s investigational gene therapy for Rett syndrome is designed to deliver a functional *MECP2* gene to the brain in patients with Rett syndrome. The REVEAL Adult Study is a Phase 1/2 study of the safety and preliminary efficacy of a single intrathecal administration of the investigational gene therapy in adult females with Rett Syndrome.

We are grateful for the continued support of the Rett syndrome community and our Rett advocacy partners. We look forward to providing further information about Taysha’s investigational gene therapy approach for Rett syndrome and the first clinical trial, the REVEAL Adult Study, soon.

Sincerely,

The Taysha Team

© Taysha Gene Therapies 2022. All rights reserved. [TSHA-RET-0227-2022]

